Clinical trials: ADPKD
Healthy Volunteers
A Study of RGLS8429 in Healthy Volunteers
Primary Objective To assess the safety and tolerability of single ascending doses of RGLS8429 Secondary Objectives To identify dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of a single SC dose of…
- Trial name
- NCT05429073
- Testing
- RGLS8429
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Regulus Therapeutics Inc.
Kidney, Polycystic, Autosomal Dominant
High Water Intake to Slow Progression of Polycystic Kidney Disease
Polycystic kidney disease (PKD) is a genetic disease that occurs in 1 in 500 individuals and leads to kidney failure in half of all affected. Currently, no treatments exist for PKD.
- Trial name
- NCT00784030
- Testing
- Water
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Autosomal Dominant Polycystic Kidney Disease
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
Currently the only approved use for rapamycin (sirolimus) is for immunosuppression after renal transplantation. This trial is designed to determine whether rapamycin is safe and effective treatment for patients with polycystic…
- Trial name
- NCT00920309
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Yale University